The breast cancer therapeutics market share is projected to grow rapidly by 2028 on account of the rapidly growing cases of breast cancer around the globe. Additionally, growing prevalence of the disease in low-to middle-income regions, such as Latin America, is also pegged to be a prominent driving factor for the market in coming years.

Last year, the WHO stated that the latest statistics released by the IARC (International Agency for Research on Cancer), now classifies breast cancer as the most common type of cancer in the world. The disease overtook lung cancer to take this number one spot.

Contrary to the general notion, breast cancer does not just affect women but can also occur in men, although the chances of it occurring in women is far higher than in men. According to the Cancer Research Institute, about 1 in 8 women and approximately 1 in 1000 men will, at some point in their lives, develop invasive breast cancer.

The coronavirus pandemic has severely exacerbated the challenges of late-stage cancer diagnosis and lack of adequate access to treatment. While this issue has emerged everywhere, they are particularly widespread in low- and middle-income nations. A 2020 WHO survey has reported that cancer treatment was moderately-to-severely disrupted in over 40% of nations surveyed at the peak of the pandemic.

However, with successful vaccination drives bringing back hospital capacities to their pre-pandemic levels, the cancer therapeutics market is slated to witness an economic bounce back at a notable pace.

The overall breast cancer therapeutics market is categorized into two segments of product, and regional landscape.

The product segment is further branched off into hormonal therapy, targeted therapy, immunotherapy, and chemotherapy. Among these, the chemotherapy segment is forecast to witness substantial growth, wherein it will reach a valuation of more than USD 4.0 billion by 2028. This would mainly be owing to the significant patient preference for chemotherapy, and new product launches among others.

The immunotherapy segment is also earmarked for strong growth. While breast cancer was previously regarded as ???difficult to treat’ through immunotherapy, owing to it being immunologically ???cold’, recent clinical studies and novel drug discoveries have showcased that immunotherapy treatment possesses the potential to enhance the outcomes for many breast cancer patients.

From a regional reference frame, the Middle East & Africa breast cancer therapeutics market is expected to showcase notable growth. The segment was valued at over USD 631 million back in 2021, and is projected to witness significant growth due to high incidence of breast cancer across various countries in the region.